Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1989 1
1994 1
1995 1
1997 2
1998 1
1999 2
2000 2
2001 1
2002 3
2003 1
2004 2
2005 3
2006 1
2007 3
2008 9
2009 6
2010 11
2011 9
2012 11
2013 10
2014 8
2015 8
2016 15
2017 13
2018 8
2019 11
2020 11
2021 7
2022 6
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Neuroendocrine Carcinoma"
Page 1
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Marabelle A, et al. J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. J Clin Oncol. 2020. PMID: 31682550 Free PMC article. Clinical Trial.
Grade 5 pneumonia occurred in one patient; there were no other treatment-related fatal adverse events. CONCLUSION: Our study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable o …
Grade 5 pneumonia occurred in one patient; there were no other treatment-related fatal adverse events. CONCLUSION: Our study demonstrates th …
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC). OBJECTIVE: To identify whether EP or IP is a more effective regimen in terms of overall surviva …
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced …
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Kim S, et al. Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12. Lancet. 2022. PMID: 36108657 Free PMC article. Clinical Trial.
METHODS: In this randomised, open label, phase 2 trial, we randomly assigned adults from two cancer sites in the USA (one in Florida and one in Ohio) to group A (combined nivolumab and ipilimumab) or group B (combined nivolumab and ipilimumab plus SBRT) in a …
METHODS: In this randomised, open label, phase 2 trial, we randomly assigned adults from two cancer sites in the USA (o …
Immunotherapy for Merkel cell carcinoma.
Angeles CV, Sabel MS. Angeles CV, et al. J Surg Oncol. 2021 Mar;123(3):775-781. doi: 10.1002/jso.26319. J Surg Oncol. 2021. PMID: 33595894 Review.
Merkel cell carcinoma (MCC) is an aggressive form of skin cancer which, while chemosensitive, has high rates of relapse and chemoresistance, limiting the impact of chemotherapy. ...This review will focus on the impact of immunotherapy in unresectable and metastatic …
Merkel cell carcinoma (MCC) is an aggressive form of skin cancer which, while chemosensitive, has high rates of relapse and chemoresi …
The Landmark Series: Non-melanoma Skin Cancers.
Lee AY, Berman RS. Lee AY, et al. Ann Surg Oncol. 2020 Jan;27(1):22-27. doi: 10.1245/s10434-019-07831-9. Epub 2019 Sep 23. Ann Surg Oncol. 2020. PMID: 31549317 Review.
This review will focus on the landmark clinical trials that led to Food and Drug Administration (FDA) approval of Vismodegib for advanced basal cell carcinoma (ERIVANCE BCC) and pembrolizumab for advanced Merkel cell carcinoma (KEYNOTE-017). These trials have …
This review will focus on the landmark clinical trials that led to Food and Drug Administration (FDA) approval of Vismodegib for adva …
Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Sun TY, Hendifar A, Padda SK. Sun TY, et al. Curr Oncol Rep. 2022 Jul;24(7):819-824. doi: 10.1007/s11912-022-01253-9. Epub 2022 Mar 19. Curr Oncol Rep. 2022. PMID: 35305210 Review.
PURPOSE OF REVIEW: Lung neuroendocrine tumors (NETs)-typical carcinoids and atypical carcinoids-have unique molecular alterations that are distinct from neuroendocrine carcinomas of the lung and non-small cell lung cancers. ...Everolimus, an mTOR inhibitor and the o …
PURPOSE OF REVIEW: Lung neuroendocrine tumors (NETs)-typical carcinoids and atypical carcinoids-have unique molecular alterations tha …
Liver transplantation for malignancies.
Eghtesad B, Aucejo F. Eghtesad B, et al. J Gastrointest Cancer. 2014 Sep;45(3):353-62. doi: 10.1007/s12029-014-9590-2. J Gastrointest Cancer. 2014. PMID: 24604263 Review.
Hepatoblastoma (HB) is the most common primary liver cancer in pediatric age group. Long-term outcomes after LT in patients with unresectable tumor and good response to chemotherapy have been promising. Indication for LT for hepatic metastasis from neuroendocrine tu …
Hepatoblastoma (HB) is the most common primary liver cancer in pediatric age group. Long-term outcomes after LT in patients with unresect …
Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD, Agarwal SK, Sadowski SM. Chatani PD, et al. Front Endocrinol (Lausanne). 2021 Jan 18;11:575620. doi: 10.3389/fendo.2020.575620. eCollection 2020. Front Endocrinol (Lausanne). 2021. PMID: 33537001 Free PMC article. Review.
Pancreatic neuroendocrine tumors (PNETs) are classified based on their histologic differentiation and proliferative indices, which have been used extensively to determine prognosis. ...As a result, targeted, pathway-specific therapies have been emerging for the treatment o …
Pancreatic neuroendocrine tumors (PNETs) are classified based on their histologic differentiation and proliferative indices, which ha …
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.
Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Reinders MTM, et al. Semin Nucl Med. 2019 May;49(3):237-243. doi: 10.1053/j.semnuclmed.2019.01.008. Epub 2019 Feb 1. Semin Nucl Med. 2019. PMID: 30954190 Review.
Ongoing trials investigate the effect of (166)Ho radioembolization in patients with neuroendocrine tumor metastases, hepatocellular carcinoma, and colorectal cancer metastases. ...This paper discusses several basics and provides an overview of relevant dosing aspect …
Ongoing trials investigate the effect of (166)Ho radioembolization in patients with neuroendocrine tumor metastases, hepatocellular …
Medullary thyroid cancer.
Kebebew E, Clark OH. Kebebew E, et al. Curr Treat Options Oncol. 2000 Oct;1(4):359-67. doi: 10.1007/s11864-000-0052-7. Curr Treat Options Oncol. 2000. PMID: 12057161 Review.
A prophylactic contralateral neck dissection should be done when the primary tumor is bilateral and when there is extensive lymphadenopathy on the side of the primary tumor. Patients who have gross, unresectable residual medullary thyroid cancer should receive postoperativ …
A prophylactic contralateral neck dissection should be done when the primary tumor is bilateral and when there is extensive lymphadenopathy …
148 results